VKTX Stock: Price, Earnings History and SEC Filings
Viking Therapeutics, Inc. (VKTX) last traded at $27.28, up 1.56% on the latest session and down 16.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-1.55 against an analyst estimate of $-1.00, a miss of 55.0%.
$27.28 +1.56%
1 month-16.32%
52-week high$43.15
52-week low$23.82
Volume5.14M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VKTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 28, 2026 | $-1.55 | $-1.00 | -55.00% |
| Jun 2026 | Jul 29, 2026 | $-1.10 | $-1.21 | +9.09% |
| Mar 2026 | Apr 29, 2026 | $-1.37 | $-0.95 | -44.21% |
| Dec 2025 | Feb 11, 2026 | $-1.38 | $-0.89 | -55.06% |
VKTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for VKTX
SEC filing data is not available right now. You can search for VKTX on SEC EDGAR.
VKTX news
- VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?Oct 30, 2026 · finance.yahoo.com
- Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetOct 30, 2026 · finance.yahoo.com
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesOct 29, 2026 · finance.yahoo.com
- LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedOct 29, 2026 · finance.yahoo.com
- Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics EasesOct 29, 2026 · 247wallst.com
- VKTX Q3 Earnings Call Highlights Obesity Pipeline ProgressOct 29, 2026 · finance.yahoo.com
- Viking Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 29, 2026 · app.moby.co
- Viking Therapeutics (VKTX) Posted Wider Losses, Is The Stock Overvalued?Oct 29, 2026 · finance.yahoo.com
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX) is a US-listed public company on Nasdaq.